Sermorelin vs Tesamorelin
Both are GHRH analogs. Tesamorelin has stronger evidence for visceral adipose reduction and is FDA-approved for HIV-associated lipodystrophy. Sermorelin is shorter-acting, less expensive, and the more common general-wellness peptide.
Sermorelin is appropriate as a first-cycle general-wellness GHRH peptide under provider review.
Tesamorelin is appropriate when visceral fat reduction is a primary goal and budget supports it.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is tesamorelin stronger?
Yes — more stable molecule and stronger visceral fat evidence.
Why use sermorelin?
Cost-effective entry to GHRH peptides with provider oversight.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment